siRNA therapy reduces triglycerides in clients with uncommon condition

.RESEARCH STUDY HIGHLIGHT.19 September 2024.

Plozasiran minimized triglyceride degrees by 80% as well as reduced the risk of pancreatitis in individuals with chronic chylomicronemia, with or without a hereditary medical diagnosis.